State, markets and networks in bioeconomy knowledge value chains, pp.163-80, 2009. ,
23andMe: a new two-sided data-banking market model, BMC Med Ethics, vol.17, p.11, 2016. ,
, Committee on cancer clinical trials and the NCI cooperative group program, board on health care services-Institute of medicine. A national cancer clinical trials system for the 21 st century: reinvigorating the NCI cooperative group program, p.298, 2010.
Current developments in the regulation of direct-to-consumer genetic testing in Europe, Med Law Int, vol.15, pp.97-123, 2015. ,
Van den Cruyce E. Direct to consumer genetic testing study. Brussels : Parlement européen, 2008. ,
Les tests génétiques grand public en caméra cachée, Med Sci (Paris), vol.27, pp.103-109, 2011. ,
La propriété des données génétiques : de la donnée à l'information, Med Sci, vol.34, pp.1100-1104, 2018. ,
Preconceptional genetic carrier testing and the commercial offer directly-to-consumers, Hum Reprod Oxf Engl, vol.26, pp.972-979, 2011. ,
Vers un droit collectif sur les données de santé, Rev Droit Sanit Soc RDSS Dalloz Rev, vol.3, pp.444-56, 2018. ,
Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context, J Community Genet, vol.3, pp.105-117, 2012. ,
Guidelines 2/2018 on derogations of article 49 under regulation 2016/679. European Data Protection Board, 2018. ,
, une innovation sanitaire régulée par le marché ? In : Valat B, ed. Les marchés de la santé en France et en Europe (XIX e -XX e siècle). Toulouse : Presses Universitaires du Midi, 2000.
Les tests génétiques vendus en libre accès sur l'Internet : une médicalisation sans médecin ? Thèse de doctorat de sociologie, 2016. ,
Markets research. Direct-to-consumer genetic testing: business prospects in the United States, 2009. ,
Survey of direct-to-consumer testing statutes and regulations. Genetics and public policy center, 2007. ,
Legislation on direct-to-consumer genetic testing in seven European countries, Eur J Hum Genet, vol.20, pp.715-736, 2012. ,
Les tests génétiques grand public ont-ils une utilité clinique ?, Med Sci, vol.28, pp.325-333, 2012. ,
Tests génétiques en accès libre sur Internet : stratégies commerciales et enjeux éthiques et sociétaux, Med Sci, vol.27, pp.95-102, 2011. ,
An agenda for personalized medicine, Nature, vol.461, pp.724-730, 2009. ,
Craig Venter et son exome, Med Sci (Paris), vol.24, pp.989-90, 2008. ,
Dépistage du cancer : les promesses illusoires de Pathway Genomics, Med Sci, vol.31, pp.1137-1146, 2015. ,
Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market, J Community Genet, vol.1, pp.101-107, 2010. ,
Industry life cycles, Ind Corp Change, vol.6, pp.145-81, 1997. ,
Grandes manoeuvres autour des profils génétiques en libre accès, Med Sci (Paris), vol.30, pp.227-235, 2014. ,
Shifting metaphors in direct-to-consumer genetic testing: from genes as information to genes as big data, New Genet Soc, vol.36, pp.296-313, 2017. ,
Network dynamics and field evolution: the growth of interorganizational collaboration in the life sciences, Am J Sociol, vol.110, pp.1132-205, 2005. ,
National academy of engineering. The positive sum strategy: harnessing technology for economic growth, pp.275-305, 1986. ,
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J Immunol, vol.174, pp.7179-85, 2005. ,
Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms, J Virol, vol.62, pp.2321-2349, 1988. ,
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21), Proc Natl Acad Sci, vol.107, pp.19985-90, 2010. ,
Complement C4 prevents viral infection through capsid inactivation, Cell Host Microbe, vol.25, pp.617-646, 2019. ,
TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination, Proc Natl Acad Sci, vol.115, pp.10440-10485, 2018. ,
Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization, PLoS Pathog, vol.6, p.1000959, 2010. ,
Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control, Nat Commun, vol.9, p.450, 2018. ,
Albuminbinding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery, J Control Release, vol.237, pp.78-88, 2016. ,